13F Pro Quality Score

68.9/100

Rank #391 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

66.9/100

Profitability

72.6/100

Balance Sheet

83.7/100

Earnings Quality

74.9/100

Free Cash Flow

58.5/100

Institutional Flow

18.4/100

Revenue Scale

80.6/100

Dilution Risk

58.2/100

EHC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Encompass Health Corp (EHC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EHC at 68.9/100 on a 32-signal composite quality model, placing it at rank #391 of 2,879 stocks — the top 25% of the AI-ranked universe. EHC scores in the top quartile across balance sheet strength (83.7), revenue scale (80.6). Areas of concern include institutional flow (18.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Encompass Health Corp reports quarterly revenue of $1.6B, net income of $194.5M, an operating margin of 18.2%. Top institutional holders of EHC by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. EHC trades on the NYSE exchange and files with the SEC under CIK 785161. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EHC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Encompass Health Corp directly from SEC EDGAR. Encompass Health Corp's 13F Pro composite quality score has ranged between 8 and 70 since 2021, currently 68.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$1.6B

Net Income

Q1 2026

$194.5M

Free Cash Flow

Q1 2026

$150.7M

Operating Margin

Q1 2026

18.2%

D/E Ratio

Q1 2026

1.02

Get alerted when EHC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Encompass Health Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of EHC

Put EHC on your watchlist

Track score changes the day Encompass Health Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is EHC a good stock to buy?

13F Pro's AI-powered analysis of Encompass Health Corp (EHC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EHC are available on the EHC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own EHC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EHC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Encompass Health Corp's investment landscape.